• Bradykinin: Applied Workflows for Vascular Permeability Stud

  2026-05-15

  Bradykinin, a gold-standard endothelium-dependent vasodilator, enables high-precision research in vascular permeability, smooth muscle contraction, and inflammation pathways. This guide provides advanced workflow enhancements, actionable troubleshooting, and practical insights to maximize Bradykinin’s impact in cardiovascular and translational research.

• Mubritinib (TAK 165): Disrupting OXPHOS in Cancer & Viral Mo

  2026-05-15

  Explore how Mubritinib (TAK 165) advances cancer and virology research by targeting mitochondrial complex I and viral latency mechanisms. This article reveals in-depth mechanistic insights and practical assay guidance not covered in scenario-driven guides.

• Luminescent ATP Cell Viability Assay Kit I: Sensitivity & Me

  2026-05-14

  The Luminescent ATP Cell Viability Assay Kit I delivers ultra-sensitive, rapid cell viability measurement using luciferase luminescence detection. This ATP-based assay outperforms legacy colorimetric and fluorometric methods in sensitivity and workflow speed. Its direct, no-lysis protocol enables precision in cytotoxicity and cell metabolism assays.

• Nuanced In Vitro Drug Response Metrics in Epigenetic Cancer

  2026-05-14

  Schwartz's dissertation introduces a rigorous framework separating relative viability and fractional viability to evaluate anti-cancer drug responses in vitro. This distinction reveals the need for more nuanced assay design when studying agents like Belinostat (PXD101), enabling clearer interpretation of cytostatic and cytotoxic effects.

• Dynasore in Cancer Microbiome Research: Beyond Endocytosis I

  2026-05-13

  Explore how Dynasore, a leading dynamin GTPase inhibitor, enables advanced cancer microbiome and endocytosis research. This article reveals new experimental dimensions for Dynasore, including its impact on bacterial extracellular vesicle studies.

• Lipid Hydrolysis Control: CAY10499 in Translational Immunome

  2026-05-13

  Explore how CAY10499, a potent inhibitor of human hormone sensitive lipase and monoglyceride lipase, enables translational researchers to dissect lipid metabolism's impact on immune function in the tumor microenvironment. This thought-leadership article bridges mechanistic insight with practical strategy, highlighting the compound's selectivity, assay guidance, and emerging translational relevance beyond current ACLY-focused paradigms.

• Bradykinin (BA5201): Practical Guidance for Vascular Researc

  2026-05-12

  Bradykinin (BA5201) is a validated endothelium-dependent vasodilator used to model vascular permeability, smooth muscle contraction, and inflammation in laboratory workflows. It is not intended for diagnostic, therapeutic, or clinical applications. Researchers benefit by following evidence-based protocols and storage practices to ensure reagent integrity and reproducibility.

• Pomalidomide (CC-4047): Mechanistic Strategy for Myeloma Pro

  2026-05-12

  This thought-leadership article for translational researchers examines Pomalidomide (CC-4047) as a precision tool for dissecting multiple myeloma biology, integrating mechanistic insights, experimental best practices, and protocol optimization. Building on the latest mutational landscape studies, it provides actionable guidance for maximizing research impact in hematological malignancy and tumor microenvironment modulation.

• NFIA Orchestrates Osteoclast and Osteoblast Balance in Bone

  2026-05-11

  This study identifies nuclear factor I/A (NFIA) as a key transcriptional regulator in mesenchymal progenitor cells, coordinating the differentiation of osteoclasts and osteoblasts to maintain bone mass. The findings provide new mechanistic insight into age-related bone loss and highlight NFIA as a potential target for bone disease research.

• MDL 28170: Redefining Translational Neuroprotection Strategi

  2026-05-11

  This thought-leadership article explores the mechanistic rationale, experimental validation, and strategic application of MDL 28170—a selective calpain and cathepsin B inhibitor—for translational neuroscience and cross-domain research. It contextualizes recent evidence from studies on cognitive impairment, ischemia-reperfusion injury, and anti-parasitic applications, and delivers actionable guidance for research teams seeking robust, reproducible models. The article directly incorporates and cites recent literature and workflow resources, providing protocol parameters, benchmarking against the competitive landscape, and offering a forward-looking vision for calpain inhibition in neuroprotection and beyond.

• Applied Workflows with Caspase-3/7 Inhibitor I in Apoptosis

  2026-05-10

  Caspase-3/7 Inhibitor I, a selective and reversible caspase-7 inhibitor from APExBIO, empowers researchers to dissect caspase-dependent apoptosis with precision. Explore optimized protocols, troubleshooting tips, and insights from the latest Candida krusei-induced apoptosis models for robust, reproducible results.

• Anisomycin as a JNK Agonist: Optimizing Apoptosis Workflows

  2026-05-09

  Harness the specificity of Anisomycin as a potent JNK agonist for apoptosis research and advanced cancer cell modeling. This guide delivers actionable workflow enhancements and troubleshooting strategies, translating mechanistic breakthroughs into reproducible results across oncology and neuroscience domains.

• SD 169: Precision p38 MAPK Inhibition for Translational Rese

  2026-05-09

  This thought-leadership article illuminates the dual mechanistic and strategic value of SD 169 (indole-5-carboxamide), a selective ATP-competitive p38α/β MAPK inhibitor, for translational researchers. Blending recent breakthroughs in kinase dephosphorylation dynamics with real-world guidance on assay design and disease modeling, it positions SD 169 as a next-generation tool for inflammation, neuroregeneration, and type 1 diabetes research. Evidence from peer-reviewed and preprint studies is integrated throughout to anchor claims in current science and to clarify how this approach advances beyond typical product literature.

• BIBR 1532 Telomerase Inhibitor: Applied Workflows & Assay In

  2026-05-08

  BIBR 1532 empowers researchers with reliable, selective telomerase inhibition for cancer cell proliferation and apoptosis studies. Leverage APExBIO’s reagent for robust telomerase activity assays, advanced molecular pathway interrogation, and troubleshooting strategies that streamline translational workflows.

• Partitioning Principles: Cy5 Maleimide (Non-sulfonated) in A

  2026-05-07

  Explore how Cy5 maleimide (non-sulfonated) empowers precise protein labeling and uniquely informs studies of biomolecular partitioning, drawing on the latest research into condensate electrostatics. Discover advanced assay design strategies and practical insights not covered elsewhere.

451 records 18/31 page Previous Next First page 上5页 1617181920 下5页 Last page